Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 1074

1.

Relation of cerebrospinal fluid/plasma HIV-RNA discordance with neurocognitive impairment.

Cárdenas G, López-González M, Monzón-Falconi JF, Soto-Hernández JL, Perales-Martínez D, López-Vejar C.

Natl Med J India. 2015 Sep-Oct;28(5):228-32.

PMID:
27132951
2.

HIV moments and pre-exposure prophylaxis--Authors' reply.

Dunn DT, Gafos M, White E, McCormack S.

Lancet. 2016 Apr 9;387(10027):1508. doi: 10.1016/S0140-6736(16)00695-4. Epub 2016 Apr 7. No abstract available. Erratum in: Lancet. 2016 Apr 23;387(10029):1722.

PMID:
27115971
3.

HIV moments and pre-exposure prophylaxis.

Grant RM, Glidden DV.

Lancet. 2016 Apr 9;387(10027):1507-8. doi: 10.1016/S0140-6736(16)30125-8. Epub 2016 Apr 7. No abstract available.

PMID:
27115970
4.

UK PrEP decision re-ignites HIV activism.

[No authors listed]

Lancet. 2016 Apr 9;387(10027):1484. doi: 10.1016/S0140-6736(16)30186-6. Epub 2016 Apr 7. No abstract available.

PMID:
27115959
5.

Care of Patients With HIV Infection: Antiretroviral Drug Regimens.

Bolduc P, Roder N, Colgate E, Cheeseman SH.

FP Essent. 2016 Apr;443:23-30. Review.

PMID:
27092564
6.

Pre-exposure Prophylaxis in Primary Care--A New Era in HIV Prevention.

Petroll AE, Staden RA, Westergaard RP.

WMJ. 2016 Feb;115(1):6-8. No abstract available.

7.

[HIV pre-exposure prophylaxis does not increase the rate of STI].

Blondel N.

Rev Med Suisse. 2016 Jan 27;12(503):236. French. No abstract available.

PMID:
26939198
8.

Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.

Overton ET, Tebas P, Coate B, Ryan R, Perniciaro A, Dayaram YK, De La Rosa G, Baugh BP.

HIV Clin Trials. 2016 Mar;17(2):72-7. doi: 10.1080/15284336.2016.1141468.

PMID:
26917112
9.

Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.

Mugwanya KK, Wyatt C, Celum C, Donnell D, Kiarie J, Ronald A, Baeten JM; Partners PrEP Study Team.

J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):374-80. doi: 10.1097/QAI.0000000000000868.

PMID:
26914909
10.

Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.

Porter DP, Toma J, Tan Y, Solberg O, Cai S, Kulkarni R, Andreatta K, Lie Y, Chuck SK, Palella F, Miller MD, White KL.

HIV Clin Trials. 2016 Feb;17(1):29-37. doi: 10.1080/15284336.2015.1115585.

PMID:
26899540
11.

Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.

Margot NA, Kitrinos KM, Fordyce M, McCallister S, Miller MD, Callebaut C.

HIV Clin Trials. 2016 Mar;17(2):78-87. doi: 10.1080/15284336.2016.1142731.

PMID:
26892863
12.

Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.

Mirembe BG, Kelly CW, Mgodi N, Greenspan S, Dai JY, Mayo A, Piper J, Akello CA, Kiweewa FM, Magure T, Nakabiito C, Marrazzo JM, Chirenje ZM, Riddler SA; MTN-003B Protocol Team.

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):287-94. doi: 10.1097/QAI.0000000000000858.

13.

Genvoya--a new 4-drug combination for HIV.

[No authors listed]

Med Lett Drugs Ther. 2016 Feb 15;58(1488):19-21. No abstract available.

PMID:
26859659
14.

Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort.

Neukam K, Mira JA, Collado A, Rivero-Juárez A, Monje-Agudo P, Ruiz-Morales J, Ríos MJ, Merino D, Téllez F, Pérez-Camacho I, Gálvez-Contreras MC, Rivero A, Pineda JA; HEPAVIR SEG-HEP-2007 Study Group of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI).

PLoS One. 2016 Feb 5;11(2):e0148104. doi: 10.1371/journal.pone.0148104. eCollection 2016.

15.

Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States.

Sweet DE, Altice FL, Cohen CJ, Vandewalle B.

PLoS One. 2016 Jan 25;11(1):e0147821. doi: 10.1371/journal.pone.0147821. eCollection 2016.

16.

Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.

Serrano-Villar S, Sainz T, Ma ZM, Utay NS, Chun TW, Mann S, Kashuba AD, Siewe B, Albanese A, Troia-Cancio P, Sinclair E, Somasunderam A, Yotter T, Deeks SG, Landay A, Pollard RB, Miller CJ, Moreno S, Asmuth DM.

PLoS Pathog. 2016 Jan 21;12(1):e1005381. doi: 10.1371/journal.ppat.1005381. eCollection 2016 Jan. Erratum in: PLoS Pathog. 2016 Mar;12(3):e1005540. Wook-Chun, Tae [corrected to Chun, Tae-Wook].

17.

[HIV: France authorizes and fully reimburses Truvada prophylaxis].

Nau JY.

Rev Med Suisse. 2015 Dec 2;11(497):2302-3. French. No abstract available.

PMID:
26785529
18.

ACP Journal Club. Preexposure tenofovir-emtricitabine reduced HIV infection in men who have unprotected anal sex with men.

Sacks HS.

Ann Intern Med. 2016 Jan 19;164(2):JC3. doi: 10.7326/ACPJC-2016-164-2-003. No abstract available.

PMID:
26784493
19.

[Miscellaneous - profound coma, smoking and AIDS].

Nau JY.

Rev Med Suisse. 2015 Nov 18;11(495):2202-3. French. No abstract available.

PMID:
26742249
20.

HOW DO I PAY FOR PrEP?

Evans D.

Posit Aware. 2015 Summer;27(5):18-9. No abstract available.

PMID:
26714339
Items per page

Supplemental Content

Loading ...
Write to the Help Desk